Stock Analiz

Inmune Bio, Inc. INMB

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026

$1.05Market cap $33M
Open the interactive analysis →

Inmune Bio, Inc. (INMB) is a healthcare company listed in the US with a market value of about $33M. In fiscal year 2025 it had revenue of $50000 and net income of -$46M, a net margin of -91866.0%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 35% a year, a 5-year average ROIC of -65%.

About Inmune Bio

Inmune Bio is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2019. Revenue went from $11000 in 2020 to $50000 in 2025, growth of about 35.4% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 38% over three years (dilution for shareholders). It spends 41318% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S650.1
P/B1.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-72.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)257.1%
Revenue growth (5 yrs, per year)35.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-87177.5%
ROIC (5-yr avg.)-64.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal year202520242023202220212020201920182017
Revenue$50000$14000$155000$374000$181000$11000—$0$0
Net income-$46M-$42M-$30M-$27M-$30M-$12M-$8M-$12M-$831486
Free cash flow-$24M————————
EPS (diluted)$-1.86$-2.11$-1.67$-1.52$-1.88$-1.01$-0.75$-1.43$-0.13
Net margin-91866.0%-300600.0%-19360.0%-7299.2%-16762.4%-110000.0%———
ROIC-152.4%-70.9%-49.1%-27.1%-23.9%-24.7%-25.8%-59.4%-4.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Inmune Bio pay a dividend?

Not currently.

Is Inmune Bio a good stock to buy?

We do not give buy or sell advice. Inmune Bio scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.